Change of name for Versicor

Published: 26-Mar-2003

Following its merger with Italian company Biosearch Italia to form an international biopharmaceutical company focused on the hospital market, US-based Versicor has been renamed Vicuron Pharmaceuticals.


Following its merger with Italian company Biosearch Italia to form an international biopharmaceutical company focused on the hospital market, US-based Versicor has been renamed Vicuron Pharmaceuticals.

'The merger and new corporate identity represent our focused drive to become a dominant force in the hospital market on both sides of the Atlantic,' said George F. Horner III, president and ceo of Vicuron. 'The new company has one of the strongest pipelines in the biotechnology industry for tough-to-treat hospital infections and our expanded presence better positions us to commercialise our lead products in the world's two largest pharmaceutical markets: North America and Europe.'

Vicuron's lead products are in Phase III clinical development. Anidulafungin, a novel antifungal agent for serious hospital fungal infections is nearing regulatory filing in the US by the end of April and in Europe in the second half of this year. Dalbavancin, a novel injectable hospital antibiotic for the treatment of serious Gram-positive infections is currently in two Phase III clinical trials.

You may also like